Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current treatment issues in female hyperprolactinaemia.

Pier Giorgio Crosignani1

  • 1I Clinica Ostetrica e Ginecologica, Università di Milano, Via Commenda 12, 20122 Milano, Italy. piergiorgio.crosignani@unimi.it

European Journal of Obstetrics, Gynecology, and Reproductive Biology
|November 18, 2005
PubMed
Summary

Hyperprolactinaemia, high prolactin levels, is often caused by pituitary tumors or medications. Dopamine agonists like cabergoline are effective treatments, improving symptoms and tumor size.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European society of contraception statement on contraception in obese women.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2014
Same author

Family planning 2011: better use of existing methods, new strategies and more informed choices for female contraception.

Human reproduction update·2012
Same author

Non-invasive diagnosis of endometriosis: the goal or own goal?

Human reproduction (Oxford, England)·2010
Same author

Medical treatment for rectovaginal endometriosis: what is the evidence?

Human reproduction (Oxford, England)·2009
Same author

Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy.

BMC women's health·2009
Same author

Endometriosis: current therapies and new pharmacological developments.

Drugs·2009

Area of Science:

  • Endocrinology
  • Reproductive Medicine
  • Oncology

Background:

  • Hyperprolactinaemia, elevated prolactin levels, can be physiological (pregnancy, lactation) or pathological.
  • Pathological hyperprolactinaemia is linked to gonadal dysfunction, infertility, osteoporosis, and is frequently caused by pituitary adenomas (prolactinomas).
  • Other causes include medications (e.g., antipsychotics) and idiopathic factors, with prevalence difficult to ascertain due to asymptomatic cases.

Purpose of the Study:

  • To review the causes, symptoms, and management of hyperprolactinaemia.
  • To compare the efficacy and tolerability of different pharmacological treatments, particularly dopamine agonists.
  • To discuss the safety and benefits of pregnancy in women with hyperprolactinaemia.

Main Methods:

Related Experiment Videos

  • Review of existing literature on hyperprolactinaemia, focusing on etiology, clinical presentation, and treatment outcomes.
  • Analysis of pharmacological interventions, including dopamine agonists such as bromocriptine, quinagolide, and cabergoline.
  • Evaluation of treatment strategies in the context of fertility and pregnancy.

    • Main Results:

    • Dopamine agonists are the first-line therapy for hyperprolactinaemia, effectively reducing prolactin levels and tumor size.
    • Newer dopamine agonists (quinagolide, cabergoline) offer improved efficacy and tolerability compared to bromocriptine.
    • Pregnancy is generally safe for women with hyperprolactinaemia and can be beneficial, with no increased risk of adverse outcomes when using bromocriptine.

    Conclusions:

    • Dopamine agonists are highly effective in managing hyperprolactinaemia, with newer agents providing better patient outcomes.
    • Pharmacological treatment is preferred over surgery for most patients, successfully alleviating symptoms and restoring hormonal balance.
    • Pregnancy can be safely achieved and is often beneficial for women with hyperprolactinaemia.